Depression during pregnancy is a major public health concern. It is highly prevalent and causes considerable suffering and impairment to the mother and has possible adverse consequences for the newborn. [1] [2] [3] [4] Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants during pregnancy 4 and until recently were considered safe in this period. 5 However, database and case-control studies have reported an association between SSRIs and anencephaly, craniosynostosis, omphalocele and persistent pulmonary hypertension in newborn children, although these associations have not been replicated in other studies. 4, 6 First-trimester exposure to paroxetine has been associated with cardiovascular malformations in some studies, 7, 8 however, other studies have failed to replicate this finding. 4, 9 We have conducted a meta-analysis with the aim of examining the suggested association between the use of paroxetine during pregnancy and the risk of cardiovascular defects in newborn children.
Method
We used the search engine Dialog TM (formerly, DataStar 1 ) provided by the National Library of Health that includes the following databases: PubMed, Embase, PsycINFO, Social Sciences Citation Index (SSCI), King's Fund, DH-Data, CINAHL, Allied and Complementary Medicine Database (AMED) and British Nursing Index (BNI). Combinations of the terms 'SSRI', 'selective serotonin reuptake inhibitor(s)', 'SRI', 'serotonin reuptake inhibitors', 'paroxetine', 'pregnancy', 'congenital malformation(s)', 'congenital defect(s)', 'cardiovascular malformation(s)', 'cardiac defect(s)', 'cardiovascular defect(s)', 'fetal malformation(s)' and 'fetal anomalies' were used for the search. The search was restricted to articles published in English but there was no exclusion on the basis of country, ethical approval, etc. No grey literature was searched for this review. Each abstract/title and article was scrutinised by two of the authors (N.P. and R.P.) and the differences between them were resolved by consensus. Relevant articles were hand-searched for cross-references. The GlaxoSmithKline website was searched for recent data on paroxetine. To exclude repetitive data-sets, only the study with the most updated data was taken up for analysis. A repeat data search was done in August 2012, after the first review of this article, and results were updated.
Inclusion and exclusion criteria
We included studies that met the following criteria: Aims and method To examine the association between the use of paroxetine during pregnancy and the risk of cardiovascular defects in the newborn. A systematic review of nine electronic databases was carried out and bibliographies were hand-searched for other relevant articles. Inclusion criteria for studies were the use of selective serotonin reuptake inhibitors in the first trimester of pregnancy, with separate data available for paroxetine and cardiovascular defects in newborn babies. A randomeffect model was used to combine the data.
Results A total of 11 studies were included in the analysis, concerning 4515 offspring who were exposed to paroxetine in the first trimester and 1 469 302 controls. In pooled analysis, paroxetine in the first trimester of pregnancy was slightly, but significantly, associated with a risk of cardiovascular malformations in the offspring (relative risk = 1.25, 95% CI 1.01-1.54). Separate analyses of case-control and cohort studies made this difference non-significant.
Clinical implications
This meta-analysis supports current guidelines advising not to use paroxetine in early pregnancy.
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Excluded studies are presented in online Table DS1 . The modified QUOROM Flow Chart 10 ( Fig. 1 ) was used to show the study search process.
Outcome measure
The outcome measure for this review was cardiovascular malformation in the newborn.
Data collection and analysis
We collected data from the studies that met the selection criteria. The quality of studies was assessed by criteria adapted from Centre for Reviews and Dissemination guidelines. 11 Descriptive data were mainly expressed in actual numbers of exposed mothers and controls. Where exact numbers were not available, frequencies were changed into actual numbers (described odds ratios (ORs) were used to resolve doubts). Results were presented in terms of risk ratio (RR) with 95% confidence intervals. A funnel plot was used to assess publication bias and heterogeneity among studies was analysed by the w 2 -test. A random-effect model was applied to combine the data. Subgroup analysis was carried out for cohort and case-control studies separately. Sensitivity analysis was carried out by the sequential removal of studies with maximum weight. Data analysis was performed with Review Manager (RevMan 5.0) for Windows. A checklist recommended by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group 12 was used.
Results
The systematic search identified 29 relevant studies. Only 11 studies 6, 8, 9, [13] [14] [15] [16] [17] [18] [19] 21 could be included in the analysis, 7 cohort 6,14-17,19,21 and 4 case-control studies 8, 9, 13, 18 (Table 1 ).
The total number of individuals included in the metaanalysis was 4514 in the paroxetine group and 1 469 302 in the control group.
Quality analysis
As shown in Table 1 , the studies that met the selection criteria were from all grades except grade B and the lowest grade E on the Centre for Reviews and Dissemination hierarchy of observational studies.
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Publication bias
The funnel plot (Fig. 2) shows the relative absence of smallsample sized studies which showed teratogenic effect of paroxetine. In trim-and-fill analysis, three studies on the left side of the plot were trimmed, but the adjusted risk ratio for the main analysis remained significant (RR = 1.23, 95% CI 1.05-1.42).
Test of heterogeneity
Examination of the w 2 distribution showed that there was significant heterogeneity between the studies included in the main analysis (Q = 14.34, d.f. = 10, P = 0.1). In the subgroup analysis, there was no significant heterogeneity within case-control (Q = 0.4, d.f. = 3, P = 0.9) and cohort (Q = 8.22, d.f. = 6, P = 0.2) studies.
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Potentially relevant papers identified by electronic search and screened for retrieval (n = 420)
Papers retrieved for more detailed evaluation (n = 70)
Potentially appropriate studies to be included in the meta-analysis (n = 29)
Studies included in meta-analysis (n = 11)
Papers excluded by screening of title and abstracts (n = 350)
Papers excluded (no quantitative data, previous reviews, reports (n = 41))
Studies excluded from meta-analysis for not meeting the inclusion criteria (n = 18) (see online Table DS1 ) A (highest quality): cohort (prospective study) with concurrent controls, B: cohort (prospective study) with historical controls, C: cohort (retrospective study) with concurrent controls, D: case-control (retrospective) study, E: observational study without control groups or large differences from comparisons between times and/or places.
Pooled results
Paroxetine use in the first trimester of pregnancy was found to be significantly associated with cardiovascular malformations, compared with unexposed controls (RR = 1.25, 95% CI 1.01-1.54) (Fig. 3) .
Subgroup analysis
Risk of cardiovascular malformation with paroxetine group became non-significant when data were pooled separately for case-control (RR = 1.09, 95% CI 0.91-1.30) and cohort (RR = 1.52, 95% CI 0.98-2.34) studies.
Sensitivity analysis
In sequential removal of studies with maximum effect sizes, the difference between paroxetine and the unexposed control remained significant after excluding the studies by Alwan et al 
Discussion
The validity of meta-analysis of observational studies has always been debated, as observational studies are more prone to biases when compared with the gold-standard randomised controlled trials. 22 However, a meta-analysis of observational studies seems justified for assessing the teratogenic effect of medications used during pregnancy because experimental studies cannot be conducted and large samples are required to observe rare events such as specific congenital malformations. In recognition of the limitations of meta-analysis of observational studies, we applied a random-effect model (rather than a fixed-effect model) to combine the results, as it can be applied irrespective of the level of heterogeneity of studies. Combining case-control and cohort studies is a wellrecognised practice in meta-analysis of epidemiological studies, 12 ,23 although we also carried out a subgroup analysis for case-control and cohort studies separately. Further, we performed a sensitivity analysis to assess the robustness of results. For quality analysis of the studies, the key components of design were considered, as this method has been found to be more appropriate for meta-analysis of observational studies. 12 In general, the study met the requirements of the MOOSE guidelines. 12 Although more than half of the identified studies were excluded from the analysis, most of them presented repeat data; thus, the combined results can be taken as a fair representation of the identified studies. There may be some doubts as to the reliability of actual numbers, as in some studies numbers were extrapolated from the frequencies and odds ratios; however, this should not affect the results considerably bearing in mind the large size of the collective sample. The apparent discrepancy between sample size and weight for each study (Fig. 1) corroborates the fact that in meta-analysis, weight given to a particular study depends not only on the sample size, but also on the variance of the data.
Underrepresentation of positive studies with small sample size in publication bias analysis could be a reflection of Type II error, a likely outcome in view of the rarity of the occurrence of cardiovascular defects. The trim-and-fill analysis only confirmed the limitation of this method, as it does not take into account the reasons for funnel plot asymmetry other than publication bias. Our meta-analysis, based on largest collective data sample so far, suggests that offspring of women who are exposed to paroxetine in the first trimester of pregnancy are at a small but significant increased risk of cardiovascular malformations. However, subgroup analysis and sensitivity analysis shows the fragility of this association. It is also possible that the borderline significant results of our meta-analysis could disappear, if the crude numbers used for the combined analysis were adjusted for various confounders such as maternal age, race, smoking, medical comorbidities, concomitant use of possible teratogens, etc.
Results of our meta-analysis fall in line with two other meta-analyses. 24, 25 O'Brien et al 24 separately analysed three case-control (n = 30 247) and six cohort (n = 66 409) studies and they did not find any significant association of cardiac malformation with paroxetine exposure. On the other hand, meta-analysis by Wurst et al 25 combined ten cohort and four case-control studies (n = 109 958) and found an increased prevalence of cardiac defects with first-trimester paroxetine use (OR = 1.46, 95% CI 1.17-1.82). Whether it is the large sample size which overcomes Type II error and exposes the teratogenic potential of paroxetine or too much heterogeneity (for the sake of large sample size) that brings spurious association remains debatable. In future, an analysis with large but more homogeneous data might provide the answer. In the meantime, our meta-analysis suggests that there is a possibility that exposure to paroxetine could be significantly associated with cardiovascular malformations and in that sense it supports the existing guidelines, 4, 26 which advise avoiding paroxetine use in early pregnancy.
